Hepatitis Monthly

Published by: Kowsar

Antibody against Interferon-α 2b in Serum of the Patients with Chronic Hepatitis C and its Clinical Significance: A Clinical Trial

wangjian wangjian 1 , * , Wang Pingping 1 and Xiang Guiju 1
Authors Information
1 Department of Aetiology and Immunology, Medical College, Anhui University of Science and Technology, Huainan 232001, Anhui, China
Article information
  • Hepatitis Monthly: June 30, 2009, 9 (2); e92963
  • Published Online: May 31, 2009
  • Article Type: Research Article
  • Received: May 05, 2019
  • Accepted: May 31, 2009

To Cite: wangjian W, Pingping W, Guiju X. Antibody against Interferon-α 2b in Serum of the Patients with Chronic Hepatitis C and its Clinical Significance: A Clinical Trial, Hepat Mon. 2009 ; 9(2):e92963.

Abstract
© 2009, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Fulltext
References
  • 1. <p>Akyuz F, Polat N, Kaymakoglu S, et al. Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels. World J Gastroenterol. 2005;11(45):7188-91. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16437670">[PubMed]</a></p>
  • 2. <p>Hung CH, Lee CM, Lu SN, et al. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol. 2002;17(12):1307-11. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12423276">[PubMed]</a></p>
  • 3. <p>Kasahara A, Hayashi N, Mochizuki K, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepat. 2000;7(5):343-51. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10971822">[PubMed]</a></p>
  • 4. <p>Wang C, Pflugheber J, Sumpter R, Jr., et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003;77(7):3898-912. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12634350">[PubMed]</a></p>
  • 5. <p>Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36(1):211-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12085367">[PubMed]</a></p>
  • 6. <p>Mangia A, Santoro R, Piattelli M, et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol. 2002;37(1):109-16. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12076869">[PubMed]</a></p>
  • 7. <p>Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol. 2001;99(3):320-4. <a href"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18248380">[PubMed]</a></p>
  • 8. <p>Fujimoto T, Tomimatsu M, Iga D, Endo H, Otsuka K. Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. J Gastroenterol Hepatol. 2008;23(8 Pt 2):e432-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18248380">[PubMed]</a></p>
  • 9. <p>Uka K, Suzuki F, Akuta N, et al. Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J Gastroenterol. 2006;41(5):470-5. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16799889">[PubMed]</a></p>
  • 10. <p>Murashima S, Kumashiro R, Ide T, et al. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol. 2000;62(2):185-90. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11002247">[PubMed]</a></p>
  • 11. <p>Penna A, Missale G, Lamonaca V, et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology. 2002;35(5):1225-36. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11981773">[PubMed]</a></p>
  • 12. <p>Castet V, Fournier C, Soulier A, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol. 2002;76(16):8189-99. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12134024">[PubMed]</a></p>
  • 13. <p>Zhang T, Lin RT, Li Y, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology. 2005;42(4):819-27. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16175599">[PubMed]</a></p>
  • 14. <p>Meager A. Biological assays for interferons. J Immunol Methods. 2002;261(1-2):21-36. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11861063">[PubMed]</a></p>
  • 15. <p>Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology. 2002;298(1):160-73. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12093183">[PubMed]</a></p>
  • 16. <p>Pan CH, Yang PM, Hwang LH, et al. T-cell antigenic determinants within hepatitis C virus nonstructural protein 3 and cytokine production profiles in hepatitis C. J Viral Hepat. 2002;9(4):258-64. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12081602">[PubMed]</a></p>
  • 17. <p>Bacosi M, De Angelis A, Ursitti A, et al. Association of circulating CD8(+) lymphocytes to a spontaneous and interferon-alpha induced clearance of HCV. Hepatol Res. 2002;23(3):163-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12076711">[PubMed]</a></p>
  • 18. <p>Qureshi H, Arif A, Ahmed W, et al. Role of interferon anti body in predicting the response to interferon therapy in HCV patients. J Pak Med Assoc. 2007;57(12):581-3. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18173038">[PubMed]</a></p>
  • 19. <p>Depraetere S, Van Kerschaever E, Van Vlierberghe H, et al. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J Med Virol. 2000;60(2):126-32. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10596010">[PubMed]</a></p>
  • 20. <p>Li ZW, Liu P, Bai H, Sun GJ, Sun J, Ma YM. [Study on the relationship between the efficacy of IFN and ribavirin on chronic hepatitis C and the anti-IFN antibodies]. Chinese Journal of Practical Internal Medicine. 2002;22(7):399-400.</p>
  • 21. <p>Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005;202(2):323-35. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15389589">[PubMed]</a></p>
  • 22. <p>Wang J, Xiang GJ, Liu BX. Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C. World J Gastroenterol. 2003;9(4):751-4. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12679925">[PubMed]</a></p>
  • 23. <p>Chen L, Chen P, Fan G, Li L, Liu C. [Localization of hepatitis C virus core protein in the nucleus of peripheral blood mononuclear cells of hepatitis C patients]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002;16(1):37-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11986743">[PubMed]</a></p>
  • 24. <p>Li CP, Wang KX, Wang J, Pan BR. mIL-2R, T cell subsets & hepatitis C. World J Gastroenterol. 2002;8(2):298-300. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11925611">[PubMed]</a></p>
  • 25. <p>Dominguez-Villar M, Munoz-Suano A, Anaya-Baz B, et al. Hepatitis C virus core protein up-regulates anergy-related genes and a new set of genes, which affects T cell homeostasis. J Leukoc Biol. 2007;82(5):1301-10. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17711976">[PubMed]</a></p>
  • 26. <p>Della Bella S, Crosignani A, Riva A, et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology. 2007;121(2):283-92. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17462079">[PubMed]</a></p>
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments